Table. Prognostic Nomograms for Overall Survival.
| Data collected | TCGA database | Barlin et al, 20117 | Rutten et al, 20149 | Xu et al, 20178 | Hamilton et al, 201824 |
|---|---|---|---|---|---|
| Data source | OVCA Firehose accessed July 2020 (%) | One-site prospective from MSKCC (n = 478) | Retrospective three center (n = 840) | SEER (n = 10 692) | Original collected data (n = 3010) |
| Reported nomogram OS performance | NA | C-index: 0.714 | C-index: 0.71 (95% CI, 0.69- 0.74) | C-index: 0.757 (95% CI, 0.741-0.773) | 10-y AUC: 0.729 |
| Dates of initial treatment | 1992-2013 | 1996-2004 | 1998-2010 | 2004-2013 | Not reported |
| Age | Yes (100%) |
Yes | Yes | Yes | No |
| FIGO tumor grade | Yes (99.3%) |
Yes | Yes | Yes | No |
| Preoperative albumin, g/dL | No | Yes | No | No | No |
| Max diameter residual tumor | No | Yes | Yes | No | Yes |
| Histological subtype | Yes (100%; all serous) |
Yes | Yes | No | No |
| ASA score | No | Yes | No | No | No |
| Breast/ovarian hereditary cancer syndrome | Yes (4.1%) |
Yes | Yes | No | No |
| Race | Yes (94.7%) |
No | No | Yes | No |
| Marital status | No | No | No | Yes | No |
| Tumor location | Yes (100) |
No | No | Yes | No |
| Clinical stage | Yes (99.1) |
No | No | Yes | No |
| LODDS | No | No | No | Yes | No |
| Primary vs interval surgery | No | No | Yes | No | No |
| Performance status | Yes (33.4%) |
No | No | No | No |
| Amount of ascites | No | No | No | No | Yes |
| CA-125 level | No | No | No | No | Yes |
Abbreviations: ASA, American Society of Anesthesiologists; AUC, area under the curve; CA-125, Cancer antigen 125; C-index, concordance index; FIGO, The International Federation of Gynecology and Obstetrics; MSKCC, Memorial Sloan Kettering Cancer Center; LODDS, log of odds of #pos:#neg lymph nodes; OS, overall survival; OVCA, ovarian carcinoma; SEER, Surveillance, Epidemiology, and End Results.